Acquired and Gene Fusions as Mechanisms of Resistance to Osimertinib in -Mutant Lung Cancers.
作者信息
Offin Michael, Somwar Romel, Rekhtman Natasha, Benayed Ryma, Chang Jason C, Plodkowski Andrew, Lui Allan J W, Eng Juliana, Rosenblum Marc, Li Bob T, Riely Gregory J, Rudin Charles M, Kris Mark G, Travis William, Drilon Alexander, Arcila Maria E, Ladanyi Marc, Yu Helena A
机构信息
Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY.
Memorial Sloan Kettering Cancer Center.
出版信息
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4.
Abstract
摘要
相似文献
1
Acquired and Gene Fusions as Mechanisms of Resistance to Osimertinib in -Mutant Lung Cancers.获得性和基因融合作为EGFR突变型肺癌对奥希替尼耐药的机制
JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00126. Epub 2018 Sep 4.
2
Characterization of acquired receptor tyrosine-kinase fusions as mechanisms of resistance to EGFR tyrosine-kinase inhibitors.获得性受体酪氨酸激酶融合作为对表皮生长因子受体酪氨酸激酶抑制剂耐药机制的特征分析
Cancer Manag Res. 2019 Jul 9;11:6343-6351. doi: 10.2147/CMAR.S197337. eCollection 2019.
3
Receptor Tyrosine Kinase Fusions and BRAF Kinase Fusions are Rare but Actionable Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors.受体酪氨酸激酶融合和 BRAF 激酶融合是 EGFR 酪氨酸激酶抑制剂的罕见但可治疗的耐药机制。
J Thorac Oncol. 2018 Sep;13(9):1312-1323. doi: 10.1016/j.jtho.2018.05.027. Epub 2018 Jun 5.
4
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.受体酪氨酸激酶融合作为表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的非小细胞肺癌中可利用的耐药机制
Trends Cancer. 2019 Nov;5(11):677-692. doi: 10.1016/j.trecan.2019.09.008. Epub 2019 Oct 29.
5
Gene status and clinicopathologic characteristics of lung adenocarcinomas with mediastinal lymph node metastasis.伴有纵隔淋巴结转移的肺腺癌的基因状态及临床病理特征
Oncotarget. 2016 Sep 27;7(39):63758-63766. doi: 10.18632/oncotarget.11494.
6
From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?从基因型到表型：携带RET和ROS1重排的肺腺癌是否存在相关影像学特征？
Lung Cancer. 2015 Nov;90(2):321-5. doi: 10.1016/j.lungcan.2015.09.018. Epub 2015 Sep 21.
7
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.一种用于检测肺癌中ALK、ROS1和RET融合的单管多重检测法。
J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.
8
Beyond and and gene rearrangements in non-small cell lung cancer.非小细胞肺癌中除了和基因重排之外的情况。 （你提供的原文表述不太完整准确，可能影响理解，建议检查一下原文是否正确。）
Transl Lung Cancer Res. 2017 Oct;6(5):550-559. doi: 10.21037/tlcr.2017.08.02.
9
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.ALK、ROS1 和 RET 融合在 1139 例肺腺癌中的综合研究：常见和融合模式特异性临床病理、组织学和细胞学特征。
Lung Cancer. 2014 May;84(2):121-6. doi: 10.1016/j.lungcan.2014.02.007. Epub 2014 Feb 19.
10
Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.RET重排在伴有恶性胸腔积液的转移性肺腺癌患者中的临床及预后意义
Lung Cancer. 2015 May;88(2):208-14. doi: 10.1016/j.lungcan.2015.02.018. Epub 2015 Mar 4.
引用本文的文献
1
Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management.表皮生长因子受体（EGFR）突变型非小细胞肺癌患者的个性化护理：从早期到晚期疾病管理的全程指引
CA Cancer J Clin. 2025 Sep-Oct;75(5):387-409. doi: 10.3322/caac.70024. Epub 2025 Jul 17.
2
Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib.病例报告：一名ALK重排肺腺癌患者，其KIF5B-RET融合对阿来替尼耐药，使用普拉替尼进行晚期治疗成功。
Front Genet. 2025 Jun 17;16:1569912. doi: 10.3389/fgene.2025.1569912. eCollection 2025.
3
Safety and efficacy of the combination of selpercatinib with osimertinib in NSCLC: a case report and review of the literature.塞尔帕替尼与奥希替尼联合用于非小细胞肺癌的安全性和有效性：一例病例报告及文献综述
Front Oncol. 2025 May 9;15:1580322. doi: 10.3389/fonc.2025.1580322. eCollection 2025.
4
Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Common Mutations: New Strategies.伴有表皮生长因子受体（EGFR）常见突变的非小细胞肺癌：新策略
Cancers (Basel). 2025 Apr 30;17(9):1515. doi: 10.3390/cancers17091515.
5
Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinoma.基底移位转化导致人肺腺癌对表皮生长因子受体（EGFR）治疗产生耐药性。
Nat Commun. 2025 May 11;16(1):4369. doi: 10.1038/s41467-025-59623-3.
6
Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges.第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）获得性耐药后的策略：机遇与挑战
Cancer Med. 2025 May;14(9):e70921. doi: 10.1002/cam4.70921.
7
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.克服表皮生长因子受体（EGFR）突变型肺癌对奥希替尼耐药的策略
Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.
8
ALK in cancer: from function to therapeutic targeting.癌症中的间变性淋巴瘤激酶：从功能到治疗靶点
Nat Rev Cancer. 2025 May;25(5):359-378. doi: 10.1038/s41568-025-00797-9. Epub 2025 Mar 7.
9
Possibilities of Overcoming Resistance to Osimertinib in NSCLC Patients with Mutations in the Gene.克服非小细胞肺癌患者基因发生突变后对奥希替尼耐药的可能性。
Cancers (Basel). 2025 Feb 7;17(4):563. doi: 10.3390/cancers17040563.
10
Consensus on the lung cancer management after third-generation EGFR-TKI resistance.第三代EGFR-TKI耐药后肺癌治疗的共识
Lancet Reg Health West Pac. 2024 Dec 11;53:101260. doi: 10.1016/j.lanwpc.2024.101260. eCollection 2024 Dec.
本文引用的文献
1
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib.MET 扩增型非小细胞肺癌患者奥希替尼耐药的下一代测序临床分析。
Lung Cancer. 2018 Apr;118:105-110. doi: 10.1016/j.lungcan.2018.02.007. Epub 2018 Feb 13.
2
Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance.与 EGFR 激酶抑制剂耐药相关的 EGFR 突变型肺癌中的伴随改变，以及 MTOR 作为耐药介质的特征。
Clin Cancer Res. 2018 Jul 1;24(13):3108-3118. doi: 10.1158/1078-0432.CCR-17-2961. Epub 2018 Mar 12.
3
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.探索非小细胞肺癌患者对第三代 EGFR 酪氨酸激酶抑制剂奥希替尼产生新耐药机制。
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310. Epub 2018 Mar 5.
4
-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.奥希替尼治疗进展患者组织和循环肿瘤DNA中面向溶剂前沿的表皮生长因子受体G796S突变：一例报告及文献复习
Lung Cancer (Auckl). 2017 Dec 6;8:241-247. doi: 10.2147/LCTT.S147129. eCollection 2017.
5
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
6
and anti-tumor activity of alectinib in tumor cells with NCOA4-RET.以及阿来替尼在具有NCOA4-RET的肿瘤细胞中的抗肿瘤活性。
Oncotarget. 2017 May 16;8(43):73766-73773. doi: 10.18632/oncotarget.17900. eCollection 2017 Sep 26.
7
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.FGFR3-TACC3融合作为EGFR突变的非小细胞肺癌患者对EGFR酪氨酸激酶抑制剂潜在的旁路耐药机制的出现。
Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.
8
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.肺腺癌的前瞻性综合分子特征分析，以实现患者与已批准和新兴疗法的有效匹配。
Cancer Discov. 2017 Jun;7(6):596-609. doi: 10.1158/2159-8290.CD-16-1337. Epub 2017 Mar 23.
9
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.奥希替尼治疗预处理 T790M 阳性的晚期非小细胞肺癌：AURA 研究二期扩展部分。
J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.
10
Antitumor Activity of RXDX-105 in Multiple Cancer Types with Rearrangements or Mutations.RXDX-105在多种具有重排或突变的癌症类型中的抗肿瘤活性。
Clin Cancer Res. 2017 Jun 15;23(12):2981-2990. doi: 10.1158/1078-0432.CCR-16-1887. Epub 2016 Dec 23.
Zotero 插件